≥ 95% by SDS PAGE

Borate Buffered Saline (pH 8.4 ± 0.2)

Human, baboon, Cynomologus macaque, Rhesus macaque.

≤ 30 Days 2-8˚C 

> 30 Days ≤ –20˚C

EIA、FACS、IHC、WB、IF

For Research Use Only. Not for use in diagnostic procedures.

A murine monoclonal antibody to a neoantigen on the terminal complement complex.

This monoclonal antibody was raised against purified human C9. This antibody has been shown to bind to a neoantigen expressed on SC5b-9, TCC, MAC, poly- C9 and on denatured immobilized C9.

The Terminal Complement Complex (TCC, SC5b-9) is generated by the assembly of C5 through C9 as a consequence of activation of the complement system by either the classical, lectin or alternative pathway. The membrane attack complex (MAC), a form of TCC, is a stable complex that mediates the irreversible target cell membrane damage associated with complement activation. Complexes formed in the absence of a target membrane bind to naturally occurring regulatory serum proteins, e.g. the S protein, at the C5b-7 stage of assembly forming soluble, non-lytic TCC

The specificity of the monoclonal antibody was established via a series of immunoassays. First, the antibody was shown by ELISA to bind SC5b-9 and C9 immobilized in microtiter wells, but not to immobilized C3, C5, C6, C7, C8 or S protein. Immobilized C9 is known to express antigenic determinates in common with polymeric C9. Second, free (unbound) SC5b-9, free (unbound) C9 and zymosan-activated human serum were shown (via inhibition EIA) to inhibit the binding of this antibody to immobilized SC5b-9. Subsequently, the antibody was shown to bind complement lysed sheep and rabbit erythrocytes (both of which contain TCC). The antibody therefore binds polymerized C9 present in both SC5b-9 and MAC, the two major forms of TCC.